Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Mar 04, 2020
Commentary on potential benefit to Neuren of RPD designation
Mar 04, 2020
Rare Pediatric Disease designation received from FDA
Feb 26, 2020
5 Orphan Drug programs and Rett in Phase 3 funded by partner
Feb 26, 2020
Appendix 4E and 2019 full year accounts
Feb 19, 2020
Update on trofinetide Phase 3 trial in Rett syndrome
Jan 28, 2020
Appendix 4C - quarterly
Previous
1
2
3
4
5
6
